EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study

Mamitaro Ohtsuki iD, Yukari Okubo iD, Hidehisa Saeki iD, Atsuyuki Igarashi, Shinichi Imafuku iD, Masatoshi Abe, Siddharth Chaudhari, Masafumi Yaguchi, Ayumi Emoto, Akimichi Morita iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17270 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Mamitaro Ohtsuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jichi Medical University, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Thalidomide, Product Surveillance, Postmarketing, Psoriasis, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The safety and efficacy of apremilast in psoriatic disease has been demonstrated in clinical trials, including in Japanese patients. This post‐marketing surveillance study was conducted after approval of apremalast in Japan in 2016 to evaluate the safety and effectiveness of the drug in Japanese patients with plaque psoriasis (PsO) and psoriatic arthritis (PsA) in routine clinical practice. Patients (enrolled between September 1, 2017, and August 31, 2019), were observed for 12 months after apremilast treatment initiation or until discontinuation or withdrawal. Safety was assessed by evaluating adverse reactions (ARs) and serious ARs. Effectiveness measures in PsO included the proportion of patients who achieved global improvement and Physician's Global Assessment (PGA) scores of 0/1 and the change from baseline in the Dermatology Life Quality Index (DLQI) after 6 and 12 months treatment. The safety analysis set included 1063 patients (PsO, n = 992; PsA, n = 127). ARs and serious ARs were reported in 29.4% and 0.7% of patients, respectively; most occurred

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideProduct Surveillance, PostmarketingPsoriasisAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleMiddle AgedAdultJapanTreatment OutcomeAgedArthritis, PsoriaticSeverity of Illness IndexQuality of LifeEast Asian People

Stichwörter der Autor:innen

apremilastplaque psoriasispost‐marketing surveillancepsoriatic arthritissafety

Substanzen

apremilastThalidomideAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Igarashi Dermatology Higashi-Gotanda Clinic, Tokyo, Japan.
  • Department of Dermatology, Fukuoka University, Fukuoka, Japan.
  • Kojinkai Sapporo Skin Clinic, Sapporo, Japan.

ORCID-Profile: Mamitaro Ohtsuki, Yukari Okubo, Hidehisa Saeki, Shinichi Imafuku, Akimichi Morita

Förderung

  • Amgen K.K.

Zitieren

APA

Ohtsuki, M., Okubo, Y., Saeki, H., Igarashi, A., Imafuku, S., Abe, M., Chaudhari, S., Yaguchi, M., Emoto, A., & Morita, A. (2024). Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17270

Vancouver

Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, et al. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17270

BibTeX
@article{Ohtsuki2024,
  author = {Ohtsuki, Mamitaro and Okubo, Yukari and Saeki, Hidehisa and Igarashi, Atsuyuki and Imafuku, Shinichi and Abe, Masatoshi and Chaudhari, Siddharth and Yaguchi, Masafumi and Emoto, Ayumi and Morita, Akimichi},
  title = {Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17270}
}
Kostenlos starten →